IONIS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.59 USD | -0.60% |
|
+2.24% | -17.79% |
| 04-11 | North American Morning Briefing : Stock Futures -2- | DJ |
| 04-10 | Wolfe Research Upgrades Ionis Pharmaceuticals to Outperform From Peer Perform | MT |
Chart calendar Ionis Pharmaceuticals, Inc.
a1ee315e855db29fab70ed4d0a8.elLgZP4SwwUxzw883aTiBr73FQ0iDbKcSTOBu3mJRkI.QzCQB6pF-lRp-UFmiJavNYyfIm96OOr6Hnr7wz3INHUpP6QVzCWtd1a2ZA~0988e102bcbe926ce29c5d98f1c62359
Upcoming events on Ionis Pharmaceuticals, Inc.
Past events on Ionis Pharmaceuticals, Inc.
| 08/04/2024 20:00 | Needham Healthcare Conference |
| 08/04/2024 15:00 | Olezarsen Balance Phase 3 Study Results Call |
| 07/04/2024 15:08 | American College of Cardiology Scientific Meeting |
| 07/04/2024 13:30 | American College of Cardiology Scientific Meeting |
| 06/04/2024 | American College of Cardiology Scientific Meeting |
| 20/03/2024 14:30 | Stifel CNS Day |
| 05/03/2024 16:10 | TD Cowen Health Care Conference |
| 21/02/2024 16:30 | Q4 2023 Earnings Call |
| 21/02/2024 12:00 | Q4 2023 Earnings Release |
| 10/01/2024 23:00 | JPMorgan Healthcare Conference |
| 03/12/2023 | BMO Growth & ESG Conference |
| 28/11/2023 15:00 | Piper Sandler Healthcare Conference |
| 14/11/2023 15:55 | Stifel Healthcare Conference |
| 07/11/2023 16:10 | Guggenheim Securities Inflammation & Immunology Conference |
| 02/11/2023 15:30 | Q3 2023 Earnings Call |
| 02/11/2023 11:00 | Q3 2023 Earnings Release |
| 04/10/2023 13:00 | Investor Day |
| 26/09/2023 16:00 | Olezarsen Phase 3 Topline Study Results Call |
| 12/09/2023 17:15 | Morgan Stanley Global Healthcare Conference |
| 07/09/2023 18:50 | Citi BioPharma Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 1 123 1 029 9.18% | 729 712 2.33% | 810 658 23.08% | 587 585 0.33% | 788 634 24.31% | 622 |
|
EBITDA Million USD | Released Forecast Spread | 378 267 41.94% | -159 -94,0 -68.92% | 130 -194 167.11% | -396 -342 -15.71% | -343 -399 14.09% | -527 |
|
EBIT Million USD | Released Forecast Spread | 366 286 28.03% | -172 -111 -55.2% | -30,0 -202 85.16% | -411 -362 -13.5% | -353 -464 23.98% | -578 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 347 281 23.62% | -170 -107 -59.01% | -30,0 -207 85.53% | -258 -349 26.08% | -334 -455 26.55% | -602 |
|
Net income Million USD | Released Forecast Spread | 294 258 13.81% | -451 -77,1 -484.89% | -29,0 -197 85.26% | -270 -354 23.77% | -366 -473 22.64% | -573 |
|
EPS USD | Released Forecast Spread | 2,08 1,77 17.31% | -3,23 -0,52 -516.11% | -0,20 -1,53 86.92% | -1,90 -2,60 26.96% | -2,56 -3,33 23.13% | -3,97 |
| Announcement Date | 26/02/20 | 24/02/21 | 24/02/22 | 22/02/23 | 21/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 440 284 54.89% | 142 125 13.43% | 134 143 -6.06% | 160 146 9.84% | 152 160 -5.12% | 131 127 3.24% | 188 142 32.47% | 144 136 5.58% | 325 171 90.17% | 139 | 144 | 165 | 174 | 143 |
|
EBITDA Million USD | Released Forecast Spread | 248 3,00 8160.73% | -53,8 -93,0 42.15% | -81,7 -94,0 13.05% | -55,3 -77,0 28.13% | -205 -205 0% | -111 -127 12.29% | -141 -86,0 -63.65% | -3,46 -117 97.03% | -152 | -155 | -97,1 | -104 | ||
|
EBIT Million USD | Released Forecast Spread | 221 49,5 346.62% | -57,0 -105 45.46% | -86,0 -91,5 6.01% | -59,0 -105 43.61% | -208 -157 -32.33% | -114 -138 17.55% | -91,0 -124 26.34% | -143 -153 6.77% | -6,00 -127 95.27% | -156 | -159 | -142 | -148 | -178 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 225 39,8 464.9% | -64,0 -104 38.71% | -103 -91,6 -12.4% | -47,0 -104 54.97% | -44,0 -131 66.52% | -113 -138 17.82% | -77,0 -123 37.23% | -141 -149 5.28% | -3,00 -123 97.56% | -158 | -163 | -145 | -146 | -192 |
|
Net income Million USD | Released Forecast Spread | 225 53,3 322.01% | -65,0 -101 35.75% | -105 -88,3 -18.96% | -47,0 -103 54.25% | -52,0 -130 60.12% | -124 -141 12.29% | -85,0 -123 31.12% | -147 -147 0.12% | -9,00 -117 92.3% | -155 | -159 | -144 | -146 | -192 |
|
EPS USD | Released Forecast Spread | 1,41 0,20 617.96% | -0,46 -0,72 35.92% | -0,74 -0,64 -15.94% | -0,33 -0,75 55.98% | -0,37 -0,92 59.82% | -0,87 -0,91 4.67% | -0,60 -0,88 31.71% | -1,03 -1,03 -0.01% | -0,06 -0,86 93.05% | -1,06 | -1,05 | -0,98 | -1,02 | -1,31 |
| Announcement Date | 24/02/22 | 04/05/22 | 09/08/22 | 09/11/22 | 22/02/23 | 03/05/23 | 09/08/23 | 02/11/23 | 21/02/24 | - | - | - | - | - |
| Today 21:05 | QIAGEN N.V.: Q1 2024 Earnings Release |
| 29/04/2024 | CRISPR THERAPEUTICS AG: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | DYNE THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | PROTAGONIST THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | EDITAS MEDICINE, INC.: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | AZENTA, INC.: Q2 2024 Earnings Release (Projected) |
| 01/05/2024 11:30 | UNITED THERAPEUTICS CORPORATION: Q1 2024 Earnings Release |
| 01/05/2024 11:30 | BIO-TECHNE CORPORATION: Q3 2024 Earnings Release |
| 01/05/2024 12:00 | ALKERMES PLC: Q1 2024 Earnings Release |
| 01/05/2024 | VIR BIOTECHNOLOGY, INC.: Q1 2024 Earnings Release |
Past sector events for Ionis Pharmaceuticals, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- IONS Stock
- Calendar Ionis Pharmaceuticals, Inc.
